Effervescent Tablet Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Setting up an effervescent tablet facility requires navigating a multi-agency licensing architecture centered on CDSCO for pharmaceutical manufacturing approvals. The Schedule M framework mandates specific infrastructure standards for effervescent lines, including humidity-controlled manufacturing zones maintained at 25-30% RH. The facility must obtain a Manufacturing Licence under Form 28 of the Drugs and Cosmetics Rules, 1945, with layout approval from the state drugs licensing authority prior to commencement of production.

• CDSCO Manufacturing Licence (Form 28) under Drugs and Cosmetics Act, 1940. Required for domestic manufacture of Schedule M-compliant effervescent formulations. State drugs authority inspection precedes licence grant. Timeline: 90-120 days post application.
• Schedule M Compliance Certification. Mandates environmental controls, air handling units with minimum HEPA filtration, particle count monitoring, and validated cleaning-in-place systems. Effervescent lines require dedicated humidity control separate from non-effervescent zones.
• FSSAI Product Approval for food-grade effervescents (vitamin drinks, dietary supplements). Required if the facility manufactures nutraceutical or food supplement effervescents alongside pharmaceuticals. Central licence route for interstate movement.
• BIS Certification under IS 10655 for pharmaceutical effervescent tablets. Optional but increasingly mandated by institutional buyers and hospital procurement chains. Bureau of Indian Standards testing of disintegration and effervescence parameters required.
• GST Registration and MSE Registration under Udyam Portal. MSE registration provides preference in government procurement and access to MSME-targeted credit schemes including CGTMSE-backed collateral-free loans.
• Pollution Control Board Consent under Water and Air Acts. Effervescent manufacturing involves solvent usage in granulation and coating; CTE (Consent to Establish) and CTO (Consent to Operate) required from State Pollution Control Board.
• ALMM (Approved List of Models and Manufacturers) applies to solar energy equipment if the facility deploys rooftop solar for power-intensive humidity control systems. Required for claiming benefits under MNRE schemes.
• MUDS (Modified Unified) not applicable here. Relevant MSME schemes include PMEGP for greenfield setup and SIDBI direct lending for equipment finance. GSTN, EPF, and ESI registrations standard for manufacturing establishment.

KAMRIT Financial Services LLP manages the complete regulatory filing cycle, from CDSCO Form 28 applications and Schedule M compliance documentation through FSSAI central licence procurement and BIS testing coordination. Our team liaises directly with state drug licensing authorities, pollution control boards, and BIS Regional Offices to compress the approvals timeline to under 180 days for a greenfield effervescent facility.

The effervescent tablet segment occupies a distinct niche within oral solid dosage forms, offering superior bioequivalence and patient compliance compared to conventional tablets. Unlike standard compressed tablets, effervescent formulations require controlled humidity environments, specialized granulation, and precise compression to ensure fizzing action stability. The broader oral solid dosage market includes OTC vitamin effervescents, pharmaceutical antacids, analgesics, and mineral supplements, each commanding differentiated margins.

Vitamin C effervescents have posted 18-22% annual growth on the back of immunity supplementation trends, while pharmaceutical effervescents for proton pump inhibitors and antihistamines grow at 12-15% annually. The mineral supplement segment, led by calcium and magnesium effervescents for bone health, registers 14-16% growth as geriatric disease burden expands. Energy drink precursors and sports nutrition effervescents represent an adjacent FSSAI-regulated sub-segment growing at 25%+ annually.

The clinical nutrition segment, though nascent, is expected to contribute 3-5% of total effervescent volumes by 2030. Hospital procurement channels are shifting toward unit-dose blister packs for chronic disease management, creating a parallel B2B stream. The sub-sector differentiates from allied oral solid formats through its packaging intensity, formulation sensitivity, and compliance advantages, which command a 20-30% price premium over equivalent conventional tablets.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

Effervescent tablet manufacturing demands a dedicated production line distinct from standard tablet presses. The core equipment set comprises: a high-shear granulator with integrated heating and cooling jacket for effervescent agent agglomeration; a fluidised bed dryer or turbo tray dryer for moisture control; an orbital shaker screener for particle size classification; a V-blender or octagonal blender for API and excipient homogenisation; a single-rotary or bi-layer tablet press capable of 20,000-50,000 tablets per hour with controlled compression force; and a blister packaging machine with aluminium foil and PVC/PVDC forming stations. European suppliers such asIMA Group (Italy) and Bosch Packaging (Germany) dominate the high-speed blister packaging segment with blister speeds of 200-400 strokes per minute.

For tablet presses, Fette (Germany) and Korsch (Germany) provide superior compression uniformity critical for effervescent formulations. Indian suppliers such as Cadmach and INDEX are viable for medium-scale lines at 40-50% lower CapEx. Chinese suppliers such as JCTRANS and Shanghai Fanem serve the budget segment but with higher maintenance overhead.

For a 10 crore annual revenue effervescent plant producing 50 million tablets per annum, the recommended line configuration includes: one high-shear granulator (₹35-50 lakh), one fluidised bed dryer (₹45-60 lakh), one 27-station rotary press (₹1.2-1.8 crore), and one blister line (₹1.5-2.0 crore). Energy consumption benchmarks at 850-950 kWh per million tablets, with humidity control systems adding 15-20% to the power load. Conversion cost per thousand tablets in the Indian context is ₹18-28, inclusive of packaging, at 70% capacity utilisation.

Raw material cost represents 55-65% of COGS, with citric acid, sodium bicarbonate, and tartaric acid as primary effervescent agents constituting 30-35% of input costs.

For a effervescent tablet plant project at ₹4.8 crore - ₹70 crore CapEx with a 2.2 - 4.0-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

For effervescent tablet plant at ₹4.8 crore - ₹70 crore CapEx and 2.2 - 4.0-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.